OXGN: OXiGENE, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, April 9, 4:55 PM OXiGENE (OXGN) is exploring regulatory approval for Zybrestat to treat anaplastic thyroid cancer in the European Union with a marketing authorization application under an exceptional or conditional circumstances pathway. The special conditions would allow it to receive approval without conducting another clinical trial and for substantially less cost. Shares -2% AH. Comment! [Healthcare, On the Move, Global & FX]
Thursday, March 21, 10:55 AM OXiGENE (OXGN +4%) bucks a weak tape to trade higher today, after announcing late yesterday that it's been issued a patent by the USPTO covering certain benzosuberene-based compounds, including the analogues referred to as KGP18 and KGP156 that the company is currently developing in the preclinical stage. The patent also covers methods of using those compounds to reduce blood flow to a tumor, and possibly restrain, slow, stop or reverse tumor progression. Comment! [Healthcare, On the Move]
Thursday, February 7, 1:05 PM Midday top 10 gainers: SUTR +40%. FMFC +39%. OXGN +23%. VSAT +22%. TRLG +20%. GEOS +20%. DV +18%. ARKR +17%. PLNR +16%. SCKT +15%.
Midday top 10 losers: AKAM -16%. ADEP -16%. EPAX -15%. OSUR -14%. SGMO -14%. IRBT -13%. ATML -13%. BONT -13%. RTIX -13%. PSMI -12%. Comment! [On the Move]
Thursday, February 7, 9:29 AM Oxigene (OXGN) soars 34% after saying its Zybrestat treatment for ovarian cancer was well tolerated when used in conjunction with Roche's Avastin in a Phase II trial, with no additional safety concerns. Oxigene expects patient accrual for the study to be completed within the next 3-4 months and for top-line data to be available at the end of the year. (PR) Comment! [Healthcare, On the Move]
Thursday, February 7, 9:14 AM Premarket gainers: OXGN +31%. SUTR +29%. DV +18%. BIOL +9%. AAP +9%. ORLY +9%. APPY +7%. LF +6%.
Losers: AKAM -18%. TQNT -11%. ARAY -9%. ANN -9%. GMCR -9%. NXST -6%. BBEP -6%. MWW -6%. BG -5%. ATML -5%. Comment! [On the Move]
Tuesday, November 20, 2012, 2:19 PM OxiGene (OXGN +7.7%) says results of its Phase 2 trial of Zybrestat, a treatment for patients with polypoidal choroidal vasculopathy, suggest that the drug, even if administered only as a single dose intravenously, may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with disease. The company also notes that further clinical testing with a more practical topical formulation in combination with photodynamic therapy may be warranted for further testing. Comment! [Healthcare, On the Move]
Tuesday, November 13, 2012, 1:06 PM Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its Phase 2 trial of Zybrestat, a potential treatment for patients with polypoidal choroidal vasculopathy, a degenerative eye disease with features similar to age-related macular degeneration. The data was presented today at the annual meeting of the American Academy of Ophthalmology. 1 Comment [Healthcare, On the Move]
Monday, September 17, 2012, 4:23 PM OXiGENE (OXGN) and the FDA reach a deal on a special protocol assessment for the Phase 3 trial of its thyriod cancer drug zybrestat. Shares +14.8% AH. 2 Comments [Healthcare, On the Move]
Wednesday, August 22, 2012, 4:13 PM Oxigene (OXGN) expands its zybrestat patient program with Azanta A/S to include the additional territories of Israel and South Korea, thus expanding on its existing regions consisting of the European Union, the Nordic countries, Switzerland, and Canada. Under the terms of the agreement, OXGN will provide Zybrestat to Azanta, and Azanta then serves as the exclusive distributor in the specified territory. Comment! [Healthcare]
Monday, August 6, 2012, 11:44 AM Oxigene (OXGN +17.5%) pops after saying its randomized Phase 2 study evaluating the combination of zybrestat and bevacizumab to treat patients with advanced ovarian cancer achieved important safety objectives in a scheduled interim toxicity analysis, and it's expected to continue to full enrollment. Comment! [Healthcare, On the Move]
Thursday, November 3, 2011, 6:51 PM Oxigene (OXGN) shares tumble over 35% after hours following a mixed report on its Phase 2 study of its cancer drug Zybrestat. Although tests appear to show some improvement when combined with other treatments, the drug shows no discernible survival benefit in stand-alone form. Comment! [On the Move, Healthcare]
Thursday, September 1, 2011, 10:43 AM Oxigene (OXGN -23%) sinks to a new 52-week low after halting Phase 2 and 3 studies of its thyroid cancer drug candidate Zybrestat due to lack of funding, and announces a restructuring whereby it will reduce its workforce by 60%. Comment! [Healthcare, On the Move]
Monday, June 6, 2011, 9:57 AM A good day for Oxigene (OXGN +18.5%), as shares soar on news that the biotech firm is again in compliance with Nasdaq minimum market and stock value requirements, and the company reports encouraging data on a phase 2 trial of its Zybrestat non-small cell lung cancer drug. Comment! [Healthcare, On the Move]
Tuesday, May 26, 2009, 9:01 AM Premarket gainers: MAPP +138%. CYTK +46%. BNC +15%. CPST +13%. HEB +12%. OXGN +9%. UTHR +8%. FEED +7%. Q +6%. ALTI +5%. ARNA +4%.
Losers: TMS +13%. CIM -10%. AIB -7%. GM -6%. CSIQ -6%. FSLR -5%. AIG -5%. DNN -5%. VE -4%. Comment!

OXGN OXiGENE, Inc.

OXGN

OXiGENE, Inc.